---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006782"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:16:40.974642+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma reports 17% revenue growth to $42M in FY2022; adj. EPS $0.14

## Summary
- FY2022 revenue $42.0M (+17% YoY); net loss $5.6M ($0.38/sh); adj. earnings $2.1M ($0.14/sh) vs adj. loss $1.2M in 2021.
- Q4 revenue $9.1M; net loss $2.4M; adj. loss $0.7M ($0.05/sh) vs adj. loss $1.9M in Q4 2021.
- Cash from operations $8.5M vs $6.3M prior year; balance sheet: $20M cash, $57M liabilities, $36M equity.
- Product revenue: Kristalose $15.2M, Sancuso $13.2M, Vibativ $7.5M, Caldolor $4.8M.
- Acquired Sancuso from Kyowa Kirin in 2022; new Nashville HQ; international partnerships for Vibativ and Caldolor.

## SEC filing metadata
- accession: 0001628280-23-006782
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/0001628280-23-006782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/cpix-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006782
- JSON: https://secwatch.observer/filing/0001628280-23-006782.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006782.txt

## Key facts
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported full year 2022 results: revenue Net revenues were $42.0 million, net income Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year., EPS $0.38 per share.
  - Period: full year 2022
  - Revenue: Net revenues were $42.0 million
  - Net income: Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year.
  - EPS: $0.38 per share
  - Result: reported results
  source text: (NASDAQ: CPIX) , a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. Net revenues grew 17% over the prior year to $42 million, resulting in $8 million in cash flow from operations. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. Total liabilities were
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/0001628280-23-006782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.